• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Wims Morris Leslie

    5/9/25 4:51:44 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wims Morris Leslie

    (Last) (First) (Middle)
    C/O IQVIA HOLDINGS INC.
    2400 ELLIS ROAD

    (Street)
    DURHAM NC 27703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IQVIA HOLDINGS INC. [ IQV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Deferred Shares (1) 05/07/2025 A 179 (1) (1) Common Stock 179 $153.3 4,452 D
    Explanation of Responses:
    1. Each deferred share is convertible into one share of common stock of IQVIA Holdings Inc. (the "Issuer") upon settlement. The deferred shares become settleable, in accordance with the Issuer's Non-Employee Director Deferral Plan, when the reporting person ceases to be a director, upon a change in control of the Company, or upon death of the reporting person. There is no expiry date.
    Remarks:
    /s/ Matthew Gilmartin, Attorney-in-Fact for Leslie Wims Morris 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IQV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    2/3/2025Buy → Neutral
    BTIG Research
    12/20/2024$250.00Overweight
    Stephens
    10/14/2024Buy
    Redburn Atlantic
    9/4/2024$275.00Outperform
    RBC Capital Mkts
    7/24/2024$266.00 → $242.00Buy → Hold
    Jefferies
    6/6/2024$270.00Buy
    Goldman
    More analyst ratings

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wims Morris Leslie

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:44 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Goggins Colleen A

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:51:17 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Fasano Jim

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      5/9/25 4:50:50 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IQVIA downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

      4/25/25 8:30:17 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by Barclays with a new price target

      Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00

      4/10/25 8:49:29 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA downgraded by BTIG Research

      BTIG Research downgraded IQVIA from Buy to Neutral

      2/3/25 8:45:01 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

      4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

      2/7/25 7:03:59 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

      Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 17, 2025 /PRNewswire/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB:AVAI), IQVIA Holdings Inc. (NYSE:IQV), S

      6/17/25 10:17:00 AM ET
      $CI
      $IQV
      $RDNT
      $SOUN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Computer Software: Prepackaged Software
    • IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement'

      IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that helps patients and their caregivers participate in decentralized clinical trials around the world. The platform is configurable, multilingual and compatible with web, iOS and Android and is available across many geographic regions, increasing p

      6/16/25 9:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • IQVIA Launches New AI Agents for Life Sciences and Healthcare

      IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry backed by deep industry expertise and powerful technology partnersh

      6/11/25 7:00:00 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $IQV
    SEC Filings

    See more
    • IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/4/25 4:30:40 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by IQVIA Holdings Inc.

      8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

      6/2/25 5:22:00 PM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.

      SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

      5/9/25 11:41:43 AM ET
      $IQV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care